Abstract
The impact of distinct disease-modifying therapies (DMTs) on severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune-responses in patients with MS receiving interferon beta, natalizumab, and ocrelizumab pre-vaccination and 6 weeks post second SARS-CoV-2 vaccination. Healthy individuals and interferon beta-treated patients generated robust humoral and cellular immune-responses. Although humoral immune responses were diminished in ocrelizumab-treated patients, cellular immune-responses were reduced in natalizumab-treated patients. Thus, both humoral and cellular immune responses should be closely monitored in patients on DMTs. Whereas patients with a poor cellular immune-response may benefit from additional vaccination cycles, patients with a diminished humoral immune-response may benefit from a treatment with SARS-CoV-2 antibodies in case of an infection.
【초록키워드】 Treatment, SARS-CoV-2, vaccination, therapy, multiple sclerosis, Cellular immune response, Infection, interferon, SARS-CoV-2 antibody, Patient, humoral immune response, patients, SARS-CoV-2 vaccination, cellular, humoral, interferon beta, vaccination efficacy, individual, pre-vaccination, benefit, robust, investigated, receiving, reduced, 【제목키워드】 therapy, Impact, Patient, SARS-CoV-2 vaccination, cellular, humoral,